| P50 | author | Geneviève Chêne | Q33101711 |
| | Pascale Trimoulet | Q47006535 |
| | Guillaume Penaranda | Q56851127 |
| | Patrick Marcellin | Q89798262 |
| P2093 | author name string | Yves Benhamou | |
| | Marc Bourlière | |
| | Philippe Halfon | |
| | Vincent Leroy | |
| | Jean-Pierre Bronowicki | |
| | Patrice Couzigou | |
| | Juliette Foucher | |
| | Sophie Pérusat | |
| | ANRS HC16 GAMMATRI Study Group | |
| P2860 | cites work | Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 |
| | Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378] | Q24805127 |
| | Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 |
| | Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Q28269827 |
| | IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 |
| | Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin | Q33905877 |
| | Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. | Q35769129 |
| | Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies | Q36346436 |
| | Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients | Q39507187 |
| | Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. | Q40862556 |
| | Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients | Q42602376 |
| | Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy | Q42985235 |
| | Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study | Q42997157 |
| | Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy | Q44089257 |
| | Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection | Q45776314 |
| | Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-α | Q56539637 |
| | Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C | Q57004851 |
| | Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations | Q67985671 |
| | Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN | Q71818520 |
| | Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha | Q73572698 |
| | Natural history of hepatitis C | Q80384219 |
| | Course and outcome of hepatitis C | Q115101371 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ribavirin | Q421862 |
| | pegylated interferon | Q7160835 |
| | chronic hepatitis C | Q55779873 |
| P304 | page(s) | 2027-2031 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Journal of Medical Virology | Q15716684 |
| P1476 | title | Neutralizing antibodies to interferon‐α and circulating interferon in patients with chronic hepatitis C non‐responding to pegylated interferon plus ribavirin re‐treated by pegylated interferon‐α‐2a and ribavirin (ANRS HC16 GAMMATRI substudy*) | |
| P478 | volume | 82 | |